1. Forde K, Reddy KR, Troxel AB, et al. Racial and ethnic differences in presentation, etiology, and outcomes of acute liver failure in the United States. Clin Gastroenterol Hepatol. 2009;7:1121–1126.
2. Lee WM. Acute liver failure in the United States. Semin Liver Dis. 2003;6:288–294.
3. Raschke RA, Curry SC, Rempe S, et al. Results of a protocol for the management of patients with fulminant liver failure. Crit Care Med. 2008;36:2244–2248.
4. Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the US Acute Liver Failure Study Group. Crit Care Med. 2007;35:2498–2508.
5. Trey C, Davidson C. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282–298.
6. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993 Jul 31; 342(8866):273–275.
7. Gimson AE, O'Grady J, Ede RJ, et al. Late onset hepatic failure: clinical serological and histological features. Hepatology. 1986;6:288–294.
8. Myers RP, Leung Y, Shaheen AA, et al. Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with
acetaminophen overdose and hepatotoxicity using administrative data.
BMC Health Serv Res. 2007;7:159.
9. Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology. 208;47:1401–1415.
10. Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg. 2003;138:852–858.
11. Suzuki A, Yuen N, Walsh J, et al. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol. 2009;7(8):882–888.
12. Fosnocht D, Taylor JR, Caravati EM. Emergency department knowledge concerning
acetaminophen (paracetamol) in over-the-counter and prescription analgesics.
Emerg Med J. 2008;25:213–216.
13. Taylor RM, Davern T, Munoz S, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology. 2006;40:1589–1597.
14. Fontana R. Acute liver failure including
acetaminophen overdose.
Med Clin North Am. 2008;92:761–794.
15. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl. 2009;15:719–729.
16. Larson AM, Polson J, Fontana RJ, et al.
Acetaminophen induced acute liver failure: results of a United States multi-center prospective study.
Hepatology. 2005;45:1364–1372.
17. Nourjah P, Ahmad SR, Karwoski C, et al. Estimates of
acetaminophen associated overdoses in the United States.
Pharmacoepidemiol Drug Saf. 2006;15:398–405.
18. Daly FFS, O'Malley GF, Heard K, et al. Prospective evaluation of repeated supratherapeutic
acetaminophen ingestion.
Ann Emerg Med. 2004;44:393–398.
19. Davern TJ II, James LP, Hinson JA, et al. Measurement of serum acetaminophen–protein adducts in patients with acute liver failure. Gastroenterology. 2006;130:687–694.
20. O'Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–445.
21. Moller HJ, Gronbaek H, Schiodt FV, et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol. 2007;47:671–676.
22. Bernal W, Donaldson N, Wyncoll D, et al. Blood lactate as an early predictor of outcome in paracetamol induced acute liver failure: a cohort study. Lancet. 2002;359: 556–562.
23. Katoonizadeh A, Decaestecker J, Wilmer A, et al. MELD score to predict outcome in adult patients with non-acetaminophen induced acute liver failure. Liver Int. 2007;27:329–334.
24. Taylor RM, Davern T, Santiago M, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology. 2006;44:1589–1597.
25. Schmidt L, Larsen FS. Prognostic implications of hyperlactatemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminophen-induced acute liver failure. Crit Care Med. 2006;34:337–343.
26. Shawcross DL, Davies NA, Mookerjee RP, et al. Worsening cerebral hyperemia by the administration of
terlipressin in acute liver failure with severe encephalopathy.
Hepatology. 2004;39:471–475.
27. Contant CF, Valadka AB, Gopinath SP, et al. Adult respiratory distress syndrome: a complication of induced hypertension after severe head injury. J Neurosurg. 2001;95(4):560–568.
28. Porte RJ, Caldwell SH. The role of recombinant factor VIIa in liver transplantation. Liver Transpl. 2005;11(8): 872–874.
29. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127–2137.
30. Funk GC, Dobeer D, Kneidinger N, et al. Acid–base disturbances in critically ill patients with cirrhosis. Liver Int. 2007;27:901–909.
31. Naka T, Bellomo R, Morimatsu H, et al. Acid–base balance in combined severe hepatic and renal failure: a quantitative analysis. Int J Artif Organs. 2008;31(4):288–294.
32. Yun BC, Kim WR, Benson JT, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology. 2009;49:1610–1616.
33. Mazer M, Perrone J. Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management. J Med Toxicol. 2008;4:1–6.
34. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856–864.
35. McKenzie TJ, Lillegard JB, Nyberg SL. Artificial and bioartificial liver support. Semin Liver Dis. 2008;28:210–217.
36. Ferraz-Neto BH, Moraes-Junior JM, Hidalgo R, et al. Total hepatectomy and liver transplantation as a two-stage procedure for toxic liver: case reports. Transplant Proc. 2008;40:814.
37. Albrecht J, Norenberg MD.
Glutamine: a Trojan horse in ammonia neurotoxicity.
Hepatology. 2006;44(4):788–794.
38. Larsen FS, Gottstein J, Blei AT. Cerebral hyperemia and nitric oxide synthase in rats with ammonia-induced brain edema. J Hepatol. 2001;34(4):548–554.
39. Larsen FS, Knudsen GM, Hansen BA. Pathophysiological changes in cerebral circulation, oxidative metabolism and blood–brain barrier in patients with acute liver failure. Tailored cerebral
oxygen utilization.
J Hepatol. 1997;27(1):231–238.
40. Jalan R, Olde Damink SW, Ter Steege JC, et al. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol. 2004;41(4):613–620.
41. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947–954.
42. McGuire G, Crossley D, Richards J, et al. Effects of varying levels of positive end-expiratory pressure on intracranial pressure and cerebral perfusion pressure. Crit Care Med. 1997;25(6):1059–1062.
43. Ede RJ, Gimson AE, Bihari D, et al. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol. 1986;2(1):43–51.
44. Gray WP, Palmer JD, Gill J, et al. A clinical study of parenchymal and subdural miniature strain-gauge transducers for monitoring intracranial pressure. Neurosurgery. 1996;39(5):927–931. Discussion 931–932.
45. Figaji AA, Zwane E, Fieggen AG, et al. Transcranial Doppler pulsatility index is not a reliable indicator of intracranial pressure in children with severe traumatic brain injury. Surg Neurol. 2009;72(4):389–394.
46. Ellis AJ, Wendon JA, Williams R. Subclinical seizure activity and prophylactic
phenytoin infusion in acute liver failure: a controlled clinical trial.
Hepatology. 2000;32(3):536–541.
47. Bhatia V, Batra Y, Acharya SK. Prophylactic
phenytoin does not improve cerebral edema or survival in acute liver failure—a controlled clinical trial.
J Hepatol. 2004;41(1):89–96.
48. Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit Care Med. 2009;37(7 suppl): S258–S264.